HK Stock Market Move | CUTIA-B (02487) rose more than 4%. CU-10201 (Topical 4% minocycline foam) received approval from the National Medical Products Administration to be marketed.

CUTIA-B (02487) rose more than 4%, with a 4.14% increase to HKD 9.8 by the time of writing, with a trading volume of HKD 4.0826 million. On the news front, CUTIA-B announced that the group's CU-10201 (topical 4% minocycline foam) has received approval from the National Medical Products Administration of the People's Republic of China for listing. The indication for CU-10201 is the treatment of non-nodular moderate to severe acne, and it is suitable for use in children aged nine and above and adult patients. CICC previously released a research report stating that 2025 is a key commercial year for Kedi, as it is expected to launch three core products, CU-40102, CU-10201, and CU-30101, in the next 12 months. The unique positioning and first-mover advantage of these products are expected to support exponential growth prospects.